| Literature DB >> 35927678 |
Chioma L Odimegwu1, Anthony N Ikefuna1, Henrietta U Okafor1, Theresa Nwagha2, Agozie Ubesie1, Josephat M Chinawa3.
Abstract
BACKGROUND: Haemostatic derangements are thought to be due to an imbalance between hepatic synthesis of pro-coagulants and urinary losses of anticoagulants.Entities:
Keywords: Children; Coagulation; Haemostasis; Nephrotic syndrome; Nigeria
Mesh:
Substances:
Year: 2022 PMID: 35927678 PMCID: PMC9351170 DOI: 10.1186/s12882-022-02894-5
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.585
Socio-demographic characteristics of the study participants
| Children with Nephrotic Syndrome (Subjects) | Children without Nephrotic syndrome (Controls) | ||
|---|---|---|---|
| Sample size (N) | 46 | 46 | |
| Sex (n %) | |||
| Female | 18 (38) | 18 (38) | |
| Male | 28 (61) | 28 (61) | |
| Age (years) | |||
| Median | 11.0 | 11.0 | |
| IQR | 8.0 – 16.0 | 8.0 – 15.25 | |
| 95% CI | 10.2 – 12.9 | 10.1 – 12.8 | |
SD Standard deviation, CI Confidence Interval, IQR Inter-quartile range
Coagulation profile of children with and without nephrotic syndrome
| Variable (unit) | Children with nephrotic syndrome | Children without nephrotic syndrome | |
|---|---|---|---|
| Median | 2.9 | 2.9 | |
| IQR | 2.1 -4.9 | 2.3 – 3.4 | |
| 95% CI of Mean | 2.9 – 3.9 | 2.7 – 3.2 | |
| Median | 45.0 | 42.0 | |
| IQR | 39.0 -57.0 | 38.0—45.3 | |
| 95% CI of Mean | 45.48 – 53.12 | 40.7 – 45.9 | |
| Median | 12.0 | 13.0 | |
| IQR | 11.0 – 13.0 | 12.0 – 14.0 | |
| 95% CI of Mean | 11.2 – 14.3 | 12.7 – 14.2 | |
| Median | 0.9 | 1.0 | |
| IQR | 0.8 – 1.0 | 1.0 -1.1 | |
| 95% CI of Mean | 0.9 – 1.1 | 1.0 – 1.1 | |
| Median | 258 | 235 | |
| IQR | 181 – 339 | 197 – 278 | |
| 95% CI of Mean | 240 – 308 | 225 – 267 | |
SD Standard deviation, IQR Inter-quartile range, APTT Activated partial thromboplastin time, PT Prothrombin time, INR International normalized ratio, AT Antithrombin, CI Confidence interval
* Statistically significant (p < 0.05)
Coagulation profile in various disease state and control
| New Disease | Relapse | Remission | Control | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | 19 | 20 | 46 | ||||||||
| Median | |||||||||||
| Median | 4.9 | 4.1 | 2.3 | 3.0 | |||||||
| IQR | 0.9 -6.2 | 2.3 – 5.5 | 1.9 – 2.6 | 2.4 – 4.0 | |||||||
| Median | 141.0 | 142.0 | 143.5 | 131.0 | |||||||
| IQR | 118.0 – 148.0 | 128.0 – 152.0 | 130.5 -149.0 | 125.0 -146.0 | |||||||
| Median | 43.0 | 46.0 | 39.8 -50.0 | 42.0 | |||||||
| IQR | 38.0 – 69.5 | 39.8 -68.3 | 38.0 -45.3 | ||||||||
ND New Disease, Con Control, Rel Relapse, Rem Remission, SD Standard deviation, IQR Inter-quartile range, Plt Platelet, APTT Activated partial thromboplastin time, PT Prothrombin time, INR International normalized ratio, AT Antithrombin, Fib Fibrinogen
* Statistically significant (p < 0.05)
Coagulation profile in various disease state and control
| New Disease | Relapse | Remission | Control | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | 19 | 20 | 46 | ||||||||
| Median | 12.0 | 12.0 | 12.0 | 13.0 | |||||||
| IQR | 12.0 – 15.0 | 10.0 -13.0 | 11.0 – 13.0 | 12.0 – 14.0 | |||||||
| Median | 1.1 | 0.9 | 0.9 | 1.0 | |||||||
| IQR | 0.9 – 1.2 | 0.8 – 1.0 | 0.8 – 1.0 | 0.9 -1.1 | |||||||
| Median | 432 | 259 | 233 | 235 | |||||||
| IQR | 268—512 | 165—301 | 181—274 | 197—278 | |||||||
ND New Disease, Con Control, Rel Relapse, Rem Remission, SD Standard deviation, IQR Inter-quartile range, Plt Platelet, APTT Activated partial thromboplastin time, PT Prothrombin time, INR International normalized ratio, AT Antithrombin, Fib Fibrinogen
* Statistically significant (p < 0.05)
Coagulation profile steroid-sensitive and steroid resistant nephrotic syndrome and controls
| SSNS | SRNS | CS | Group | SS vs SR | SS vs CS | SR vs CS | |
|---|---|---|---|---|---|---|---|
| Median | 2.4 | 3.7 | 3 | ||||
| IQR | 2.0 – 3.3 | 2.0—5.5 | 2.4 – 4.0 | ||||
| Median | 142.5 | 144 | 131 | ||||
| IQR | 128.0–149.0 | 128.0 -152.0 | 125—146 | ||||
| Median | 49 | 43 | 42 | ||||
| IQR | 40.3 – 64.3 | 39.0—50.0 | 38.0—45.3 | ||||
| Median | 12 | 11 | 13 | ||||
| IQR | 11.0 – 13.0 | 10.0 -12.0 | 12.0 -14.0 | ||||
| Median | 0.9 | 0.8 | 1 | ||||
| IQR | 0.9 -1.0 | 0.8—0.9 | 1.0—1.1 | ||||
( | 238 | 257 | 235 | ||||
| IQR | 183 -328 | 152 -180 | 197 -277 | ||||
SR Steroid resistant, SS Steroid sensitive, CS Controls, vs Versus, SSNS Steroid sensitive nephrotic syndrome, SRNS Steroid resistant nephrotic syndrome, SD Standard deviation, IQR Inter-quartile range, Plt Platelet, APTT Activated partial thromboplastin time, PT Prothrombin time, INR International normalized ratio, AT Antithrombin, Fib Fibrinogen
* Statistically significant (p < 0.05)
+ Group P value = trend towards statistical significance
Logistic regression of coagulation variables on steroid response
| Regression | Odds | Lower 95% | Upper 95% | ||
|---|---|---|---|---|---|
| Independent | Coefficient | Ratio | Confidence | Confidence | |
| Variable | b(i) | Exp(b(i)) | Limit | Limit | |
| Fibrinogen | -0.54238 | 0.58 | 0.33 | 1.02 | |
| PT | 0.31857 | 1.38 | 0.91 | 2.07 |
Estimated Logistic Regression Model(s)
Model For Steroid Sensitive Nephrotic Syndrome
2.55–0.50*Fib + 3.69*INR -0.23*BMI
Logistic regression of coagulation variables and steroid response pattern on disease state
| Regression | Odds | Lower 95% | Upper 95% | |
|---|---|---|---|---|
| Independent | Coefficient | Ratio | Confidence | Confidence |
| Variable | b(i) | Exp(b(i)) | Limit | Limit |
| Fibrinogen | -2.118 | 0.12 | 0.03 | 0.56 |
| Steroid Sensitive | 3.402 | 30.03 | 2.01 | 448.04 |
Estimated Logistic Regression Model(s)
Model For Remission in Nephrotic Syndrome 9.03–2.18*Fib + 3.40*2 -0.10
Association between coagulation variables and steroid response status
| Variable | No of cases | |||
|---|---|---|---|---|
| Steroid Sensitive | Steroid Resistant | Chi Square | ||
| High Fib (> 3.5 g/L) | 1 | 8 | 9.798 | |
| Normal Fib ( 1.5 -3.5 g/L) | 22 | 6 | ||
| Low Fib (< 1.5 g/L) | 1 | 1 | ||
| High AT (> 144%) | 11 | 8 | 0.303 | 0.859 |
| Normal AT (80 -144%) | 11 | 6 | ||
| Low AT-III (< 80%) | 2 | 0 | ||
| High APTT (> 50 s) | 7 | 3 | 0.037 | 0.982 |
| Normal APTT ( 36 -50 s) | 15 | 11 | ||
| Low APTT (< 36 s) | 2 | 1 | ||
| High PT (> 16 s) | 1 | 0 | 0.335 | 0.846 |
| Normal PT (11 -16 s) | 17 | 11 | ||
| Low PT (< 11 s) | 6 | 3 | ||
| High INR (> 1.2) | 5 | 2 | 6.715 | |
| Normal INR (0.8 -1.2) | 19 | 7 | ||
| Low INR (< 0.8) | 0 | 6 | ||
High PLT (> 400 × 103 cells/mm3 | 2 | 0 | 1.459 | 0.482 |
Normal PLT (150 – 400 × 103 cells/mm3) | 18 | 12 | ||
Low PLT (< 150 × 103 cells/mm3) | 4 | 3 | ||
Key: Plt Platelet, APTT Activated partial thromboplastin time, PT Prothrombin time, INR International normalized ratio, AT Antithrombin, Fib Fibrinogen
* Statistically significant p < 0.05